NCT02403284View on ClinicalTrials.gov

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

PHASE4CompletedINTERVENTIONAL

Enrollment

97

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 28, 2021

Study Completion Date

November 1, 2023

Conditions

Insulin Resistance

Interventions

DRUG

Liraglutide

Subcutaneous injection by patient

DRUG

Sugar Pill

Subcutaneous injection daily

Trial Locations (1)

85012

Carl T. Hayden VA Medical Hospital, Phoenix

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Phoenix VA Health Care System

FED